Literature DB >> 9580623

Stabilization of vasoactive intestinal peptide by lipids.

G Gololobov1, Y Noda, S Sherman, I Rubinstein, J Baranowska-Kortylewicz, S Paul.   

Abstract

An anionic phospholipid, phosphatidylglycerol (PG), induced vasoactive intestinal peptide (VIP) to adopt a helical conformation, determined by circular dichroism studies. PG inhibited the trypsin-catalyzed, antibody-catalyzed and uncatalyzed cleavage of VIP, measured by radiometric and HPLC methods. Phosphatidylcholine, a neutral lipid, did not alter the circular dichroism spectra of VIP, and it was without detectable effect on the rates of VIP cleavage. Trypsin-catalyzed cleavage of Boc-Ile-Glu-Arg-methylcoumarinamide, a substrate unrelated in sequence to VIP, proceeded at equivalent rates in the absence and presence of PG, which suggests that the phospholipid did not exert a nonspecific inhibitory effect on the enzyme. Study of the kinetics of antibody-catalyzed VIP cleavage indicated that the inhibition by PG was due to decreased affinity for VIP, suggested by observations of increased K(m) values and unaltered Vmax values. Incorporation of VIP in the liposomes and the liposomal surface permitted maintenance of the peptide in essentially undegraded form at 37 degrees C for 8 days. The longevity of liposomal VIP administered i.v. to mice was increased by about 5-fold compared with aqueous VIP. These observations indicate that certain phospholipids and liposomes can be applied to circumvent the rapid loss of VIP in vitro and in vivo due to degradative processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580623

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  C-terminal elongation of growth-blocking peptide enhances its biological activity and micelle binding affinity.

Authors:  Yoshitaka Umetsu; Tomoyasu Aizawa; Kaori Muto; Hiroko Yamamoto; Masakatsu Kamiya; Yasuhiro Kumaki; Mineyuki Mizuguchi; Makoto Demura; Yoichi Hayakawa; Keiichi Kawano
Journal:  J Biol Chem       Date:  2009-08-26       Impact factor: 5.157

2.  Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC2 Agonism and Glucose-Dependent Insulin Secretion.

Authors:  Fabrizio Giordanetto; Jefferson D Revell; Laurent Knerr; Marie Hostettler; Amalia Paunovic; Claire Priest; Annika Janefeldt; Adrian Gill
Journal:  ACS Med Chem Lett       Date:  2013-10-16       Impact factor: 4.345

Review 3.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

4.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

5.  A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Authors:  H Onyüksel; H Ikezaki; M Patel; X P Gao; I Rubinstein
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

6.  Glucocorticoid receptor expression on acute lung injury induced by endotoxin in rats.

Authors:  Yu-Cai Zhang; Wen-Qiong Zuo; Qun-Fang Rong; Guo-Liang Teng; Yu-Ming Zhang
Journal:  World J Emerg Med       Date:  2010

7.  Micellar nanomedicine of human neuropeptide Y.

Authors:  Antonina Kuzmis; Sok Bee Lim; Esha Desai; Eunjung Jeon; Bao-Shiang Lee; Israel Rubinstein; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2011-01-25       Impact factor: 5.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.